Table 1. Patients clinic-pathologic characteristics.
| Variables | All patients | Patients with ERR | Patients without ERR |
|---|---|---|---|
| Patients enrolled, n (%) | 40 (100.0) | 30 (75.0) | 10 (25.0) |
| Gender, n (%) | |||
| Male | 19 (47.5) | 14 (46.7) | 5 (50.0) |
| Female | 21 (52.5) | 16 (53.3) | 5 (50.0) |
| Age, years | |||
| Median [range] | 62 [40–85] | 61 [40–85] | 69 [41–84] |
| Race, n (%) | |||
| European | 38 (95.0) | 28 (93.3) | 10 (100.0) |
| Others | 2 (5.0) | 2 (6.7) | 0 |
| Smoking, n (%) | |||
| Yes | 9 (22.5) | 6 (20.0) | 3 (30.0) |
| No | 30 (75.0) | 23 (76.7) | 7 (70.0) |
| Unknown | 1 (2.5) | 1 (3.3) | 0 |
| Packs, years | |||
| Median [range] | 0 [0–185] | 0 [0–185] | 0 [0–102] |
| Performance status, n (%) | |||
| 0 | 14 (35.0) | 10 (33.3) | 4 (40.0) |
| 1 | 22 (55.0) | 16 (53.3) | 6 (60.0) |
| 2 | 4 (10.0) | 4 (10.3) | 0 |
| Pathology, n (%) | |||
| Adenocarcinoma | 39 (97.5) | 29 (96.7) | 10 (100.0) |
| Others | 1 (2.5) | 1 (3.3) | 0 |
| Stage, n (%) | |||
| IIIB | 2 (5.0) | 2 (6.7) | 0 |
| IV | 38 (95.0) | 28 (93.3) | 10 (100.0) |
| Number of prior CT, n (%) | |||
| 0 | 25 (62.5) | 21 (70.0) | 4 (40.0) |
| 1 | 10 (25.0) | 7 (23.3) | 3 (30.0) |
| 2 | 3 (7.5) | 1 (3.3) | 2 (20.0) |
| >2 | 2 (5.0) | 1 (3.3) | 1 (10.0) |
| TKI, n (%) | |||
| Erlotinib | 30 (75.0) | 23 (76.7) | 7 (70.0) |
| Gefitinib | 8 (20.0) | 6 (20.0) | 2 (20.0) |
| Afatinib | 2 (5.0) | 1 (3.3) | 1 (10.0) |
ERR, early radiological response; CT, computed tomography; TKI, tyrosine kinase inhibitor.